Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Soligenix Inc chart...

About the Company

soligenix, inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous t-cell lymphoma, oral mucositis, pediatric crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.

$0M

Total Revenue

23

Employees

$6M

Market Capitalization

-0.20

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SNGX News

Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results

3d ago, source:

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...

Soligenix, Inc.

5mon ago, source: CNN

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized ...

Soligenix Announces Formation of Behçet's Disease Medical Advisory Board

1mon ago, source: Nasdaq

PRINCETON, N.J., Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products ...

Recap: Soligenix Q4 Earnings

3d ago, source:

Soligenix beat estimated earnings by 68.0%, reporting an EPS of $-0.06 versus an estimate of $-0.19. Revenue was down $160 thousand from the same period last year. Last quarter the company beat on EPS ...

Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

1mon ago, source: Morningstar

Soligenix, a late-stage biopharmaceutical company ... RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small ...

SOLIGENIX, INC.: Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results

3d ago, source: Finanznachrichten

PRINCETON, N.J., March 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products ...

Soligenix Announces Formation of Behçet's Disease Medical Advisory Board

1mon ago, source: Stockhouse

PRINCETON, N.J., Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

Soligenix Inc.

12d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Soligenix Announces Formation of Behçet's Disease Medical Advisory Board

1mon ago, source: Yahoo Finance

Phase 2a clinical study of SGX945 in Behçet's Disease initiating in 2024 PRINCETON, N.J., Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...